Please assess the completion status of the following clinical trial:

Trial Title: Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of Crohn's disease ( Lennard -Jones criteria )~2. Active Crohn's disease in the last six months to the inclusion defined as : CDAI? 220 and endoscopic or radiological criteria of activity~3. Refractory or intolerance to conventional therapy including corticosteroids , immunomodulators and anti-tumor necrosis factor-alpha~4. Presence of visible lesions by endoscopy~5. Acceptance to participate in the study and written informed consent~Exclusion Criteria:~1. No injuries in pre-screening resonance~2. Pregnancy, lactation or women of childbearing age not taking appropriate contraceptive measures~3. Patients HIV + and Hepatitis C Virus + Hepatitis B Virus +~4. Serious concomitant disease:~   * Renal failure with creatinine clearance \< 40ml / min~  * Heart disease: congestive heart failure with ejection fraction \< 45 % , atrial fibrillation treated with oral anticoagulants, uncontrolled ventricular arrhythmias , pericarditis , pleural effusion with hemodynamic~  * Neoplasms or myelodysplasia~  * Psychiatric disorders including alcohol and drugs~5. Symptoms attributable to fibrotic strictures in Crohn's disease at the discretion of the investigators~6. Diarrhea attributable to  short bowel syndrome~7. Active infection , including tuberculosis~8. Participation in research studies of new drugs in the 3 months prior to inclusion.~9. Vaccination with live/attenuated germs in the previous 3 months~10. Personal history of cancer (active or complete remission) or known family history of hereditary cancer.~11. Patients in whom , after observation of the state of their veins , these are considered inaccessible and impossible to perform apheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 10 millions dose (Type: EXPERIMENTAL): a total of 10 millions tolerogenic dendritic cells
- 100 millions dose (Type: EXPERIMENTAL): a total of 100 millions tolerogenic dendritic cells

Based on this trial design, predict the completion outcome and termination type (if applicable).